Skip to main content

Table 6 Change scores between-group and within-group in biological outcomes

From: Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial

  

Mean (SD)

Mean difference

CI 95%

t (p)

 

CRP 5th week

Experimental

4.09 (6.51)

−2.48

−10.54 to 5.57

−0.63 (0.53)

Between group

Control

6.57 (11.52)

CK 5th week

Experimental

105.36 (44.17)

−0.20

−37.92 to 37.50

−0.01 (0.99)

Control

105.57 (46.05)

  

Mean (SD)

Mean difference

CI 95%

t (p)

Within group

Experimental

Basal CRP

4.27 (5.81)

0.182

−0.47 to 0.84

0.61 (0.55)

5th week CRP

4.09 (6.51)

Control

Basal CRP

5.36 (5.13)

−1.21

−7.28 to 4.85

−0.43 (0.67)

5th week CRP

6.57 (11.52)

Experimental

Basal CK

102.36 (39.08)

−3.00

−16.17 to 10.17

−0.50 (0.62)

5th week CK

105.36 (44.17)

Control

Basal CK

112.50 (43.57)

6.92

−12.19 to 26.05

0.78 (0.44)

5th week CK

105.57 (46.05)

  1. Abbreviations: CRP C-reactive Protein, CK Creatine Kinase, SD standard deviation, CI confidence interval